Select a medication above to begin.
Invokana
canagliflozin
Adult Dosing .
Dosage forms: TAB: 100 mg, 300 mg
diabetes mellitus, type 2
- [100-300 mg PO qd]
- Start: 100 mg PO qd; Max: 300 mg/day; Info: give before 1st meal; hold tx at least 3 days before surgery/procedure if prolonged fasting
cardiovascular event risk reduction - DM type 2 pts w/ estab. cardiovascular dz
- [100 mg PO qd]
- Max: 300 mg/day; Info: give before 1st meal; may incr. dose to 300 mg PO qd if additional glycemic control needed; hold tx at least 3 days before surgery/procedure if prolonged fasting
kidney dz progression and cardiovascular-associated risk reduction - DM type 2 pts w/ nephropathy and albuminuria >300 mg/day
- [100 mg PO qd]
- Max: 300 mg/day; Info: give before 1st meal; may incr. dose to 300 mg PO qd if additional glycemic control needed; hold tx at least 3 days before surgery/procedure if prolonged fasting
renal dosing
- [diabetes mellitus, type 2]
- eGFR 30-59: max 100 mg/day; eGFR <30: avoid use for glycemic control
- HD/PD: not defined
- [all other indications]
- eGFR 30-59: max 100 mg/day; eGFR <30: avoid tx initiation; Info: if eGFR <30 during tx, may cont. 100 mg qd in pts w/ albuminuria >300 mg/day
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: TAB: 100 mg, 300 mg
diabetes mellitus, type 2
- [10 yo and older]
- Dose: 100-300 mg PO qd; Start: 100 mg PO qd; Max: 300 mg/day; Info: give before 1st meal; hold tx at least 3 days before surgery/procedure if prolonged fasting
renal dosing
- [see below]
- eGFR 30-59: max 100 mg/day; eGFR <30: avoid use for glycemic control
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined